Figure 10.
Therapeutic effects of the mitochondrial-targeting peptide nanotherapy ATTPCD NP after inhalation delivery in mice with DOX-induced heart failure. (A) The heart weight of different groups. (B) The ratios of HW/TL for different groups. (C-F) The levels of MDA (C), H2O2 (D), TNF-α (E), and MPO (F) in tissue homogenates of hearts isolated from mice treated with different formulations. Total protein contents in heart homogenates were measured by the BCA assay. (G-H) Serum levels of cTnI (G) and CK (H). (I) Representative M-mode echocardiography images of mouse hearts after different treatments. (J-K) LVEF and LVFS quantified by echocardiography. Data are mean ± SD (n = 5). Statistical significance was assessed by the one-way ANOVA with post-hoc LSD tests. *P < 0.05, **P < 0.01, ***P < 0.001.